![Transparency Market Researchが調査・発行した産業分析レポートです。旅行者下痢症治療の世界市場：薬物クラス別、病原体別、年齢別、流通経路別 / Traveler’s Diarrhea Treatment Market (Drug Class: Oral Rehydration Therapy (ORS), Antidiarrheal Agents, Antibiotics [Azithromycin, Ciprofloxacin, Quinolones, and Rifaximi], Vaccines/Prophylactics, and Others; Pathogen: Bacteria [E. Coli, Salmonella Spp, and Others], Viruses, and Protozoa; Age Group: Adults and Children; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-2JN012資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-63.gif) | • レポートコード：TPM-2JN012 • 出版社/出版日：Transparency Market Research / 2019年12月30日 • レポート形態：英文、PDF、240ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは旅行者下痢症治療の世界市場について調査・分析し、序論、仮定・研究方法、エグゼクティブサマリー、市場状況、市場動向、薬物クラス別分析、病原体別分析、年齢別分析、流通経路別分析、地域別（北米、欧州、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを含め、次の構成でお届けいたします。 ・序論 ・仮定・研究方法 ・エグゼクティブサマリー ・市場状況 ・市場動向 ・旅行者下痢症治療の世界市場：薬物クラス別 ・旅行者下痢症治療の世界市場：病原体別 ・旅行者下痢症治療の世界市場：年齢別 ・旅行者下痢症治療の世界市場：流通経路別 ・旅行者下痢症治療の世界市場：地域別（北米、欧州、アジア太平洋、中南米、中東・アフリカ） ・旅行者下痢症治療の北米市場分析・予測 ・旅行者下痢症治療の欧州市場分析・予測 ・旅行者下痢症治療のアジア太平洋市場分析・予測 ・旅行者下痢症治療の中南米市場分析・予測 ・旅行者下痢症治療の中東・アフリカ市場分析・予測 ・競争状況 |
International travel has gained significant momentum in the past decade and the trend is showing no signs of slowing down. As per the data released by the World Tourism Organization (UNWTO), an astounding 1.4 billion international tourist arrivals were recorded – a 6% rise from 2017. As per the observable trends, tourists are traveling in huge numbers to tropical and sub-tropical countries, including Thailand, Spain, and India. However, tourists are at a high risk of being exposed to diarrheal pathogens in these regions and thus, traveler’s diarrhea has emerged as one of the most common health problems faced by international travelers.
Traditionally, antibiotic prophylaxis is used to prevent traveler’s diarrhea, which is primarily caused by bacterial etiologies. The traveler’s diarrhea treatment market is expanding at a rapid pace, as awareness among travelers related to ill effects of traveler’s diarrhea is increasing. Furthermore, drug approvals by the FDA, rise in the number of research activities, and development of new therapeutics are some of the leading factors that are expected to drive the traveler’s diarrhea treatment market. The market for traveler’s diarrhea treatment is expected to reach a value of ~US$ 1.3 Bn by 2027.
Antibiotics used to treat and manage traveler’s diarrhea have evolved at a rapid pace in the past 50 years due to a range of factors, including drug resistance, costs, and side-effects. However, with consistent developments in research, new and improved treatments for traveler’s diarrhea are entering the traveler’s diarrhea treatment market.
The Food and Drug Administration (FDA) has given approval to several new treatments and drugs in recent years. For instance, Aemcolo, an oral antibacterial rifamycin, was approved by the FDA in November 2018 to treat traveler’s diarrhea caused by E.coli. Clinical studies have revealed that rifamycin has greater efficiency in reducing the symptoms of diarrhea symptoms compared to placebo. Antibiotics are primarily recommended to treat severe traveler’s diarrhea. Despite a few side effects, within the drug class segment, antibiotics are likely to stay ahead with a market share of ~51% during the forecast period. The management and treatment of traveler’s diarrhea are expected to evolve, owing to the formulation of different guidelines laid down by regulatory bodies worldwide. As per the new guidelines, the use of antibiotics for mild traveler’s diarrhea is not recommended, as they have been linked to adverse events.
Antidiarrheal agents, such as bismuth subsalicylate and loperamide, are predominantly used in conjunction with antibiotics to offer instant relief from the symptoms of traveler’s diarrhea. The treatment of traveler’s diarrhea primarily depends on the severity of the treatment. Oral rehydration solutions are ideally used to treat traveler’s diarrhea in children, infants, and geriatric population, as these patients are more susceptible to dehydration and electrolyte imbalance. The oral rehydration solution and antidiarrheal segments of the traveler’s diarrhea treatment market are collectively expected to reach a value of ~US$ 511 Mn by the end of 2027.
Traveler’s diarrhea is predominantly caused by pathogens such as viruses, bacteria, and protozoa. Of these, nearly 80% of the cases are caused by bacteria, and thus, this segment is projected to account for ~ 69% share of the traveler’s diarrhea treatment market in 2019. Viruses are the causative agents for ~5-10% cases depending on geographical location. As per the Centers for Disease Control and Prevention data, norovirus and rotavirus are the leading types of viruses that cause traveler’s diarrhea. E.coli and Salmonella Spp are the two major bacteria types responsible for traveler’s diarrhea. According to the British Medical Journal, the prevalence of traveler’s diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia. Thus, the traveler’s diarrhea treatment market is expected to grow during the forecast period.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Traveler’s Diarrhea Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Surge in Number of Travelers
4.3.1.2. Awareness Among Travelers
4.3.1.3. Evolution of Pathogens and Antimicrobial Resistance
4.3.1.4. Rise in Number of Food Contamination Cases
4.3.1.5. New Therapeutics in Development
4.3.2. Restraints
4.3.2.1. Trend of Self-medication Using OTC Products and Misuse of Antibiotics
4.3.2.2. Awareness about Hygiene
4.3.2.3. Introduction of Generic Products
4.3.3. Opportunities
4.4. Global Traveler’s Diarrhea Treatment Market Analysis and Forecasts, 2017–2027
5. Market Outlook
5.1. Overview of Guidelines for Diagnosis & Treatment of Traveler’s Diarrhea
5.2. Private/Public Sector Drug Supply Chain by Region/Country
5.3. Pipeline Analysis
5.4. Epidemiology of Traveler’s Diarrhea by Region/Sub-region
5.5. Overview of Causes/Percentage of Bacteria, Viruses and Protozoa Causing Traveler’s Diarrhea
6. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Oral Rehydration Therapy (ORS)
6.3.2. Antidiarrheal Agents
6.3.2.1. Antibiotics
6.3.2.2. Azithromycin
6.3.2.3. Ciprofloxacin
6.3.2.4. Quinolones
6.3.2.5. Rifaximin
6.3.3. Vaccines/prophylactics
6.3.4. Others
6.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Drug Class
7. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Pathogen
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027
7.3.1. Bacteria
7.3.1.1. E. Coli
7.3.1.2. Salmonella Spp
7.3.1.3. Others
7.3.2. Viruses
7.3.3. Protozoa
7.3.3.1. Giardiasis
7.3.3.2. Cryptosporidium parvum
7.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Pathogen
8. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Age
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027
8.3.1. Adults
8.3.2. Children
8.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Age
9. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
9.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Distribution Channel
10. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Region
11. North America Traveler’s Diarrhea Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2027
11.2.1. Oral Rehydration Therapy (ORS)
11.2.2. Antidiarrheal Agents
11.2.3. Antibiotics
11.2.3.1. Azithromycin
11.2.3.2. Ciprofloxacin
11.2.3.3. Quinolones
11.2.3.4. Rifaximin
11.2.4. Vaccines/prophylactics
11.2.5. Others
11.3. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027
11.3.1. Bacteria
11.3.1.1. E. Coli
11.3.1.2. Salmonella Spp
11.3.1.3. Others
11.3.2. Viruses
11.3.3. Protozoa
11.3.3.1. Giardiasis
11.3.3.2. Cryptosporidium parvum
11.4. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027
11.4.1. Adults
11.4.2. Children
11.5. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027
11.5.1. Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Online Pharmacies
11.6. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Traveler’s Diarrhea Treatment Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Pathogen
11.7.3. By Age
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Traveler’s Diarrhea Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2027
12.2.1. Oral Rehydration Therapy (ORS)
12.2.2. Antidiarrheal Agents
12.2.3. Antibiotics
12.2.3.1. Azithromycin
12.2.3.2. Ciprofloxacin
12.2.3.3. Quinolones
12.2.3.4. Rifaximin
12.2.4. Vaccines/prophylactics
12.2.5. Others
12.3. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027
12.3.1. Bacteria
12.3.1.1. E. Coli
12.3.1.2. Salmonella Spp
12.3.1.3. Others
12.3.2. Viruses
12.3.3. Protozoa
12.3.3.1. Giardiasis
12.3.3.2. Cryptosporidium parvum
12.4. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027
12.4.1. Adults
12.4.2. Children
12.5. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027
12.5.1. Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Online Pharmacies
12.6. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Traveler’s Diarrhea Treatment Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Pathogen
12.7.3. By Age
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Traveler’s Diarrhea Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Oral Rehydration Therapy (ORS)
13.2.2. Antidiarrheal Agents
13.2.3. Antibiotics
13.2.3.1. Azithromycin
13.2.3.2. Ciprofloxacin
13.2.3.3. Quinolones
13.2.3.4. Rifaximin
13.2.4. Vaccines/prophylactics
13.2.5. Others
13.3. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027
13.3.1. Bacteria
13.3.1.1. E. Coli
13.3.1.2. Salmonella Spp
13.3.1.3. Others
13.3.2. Viruses
13.3.3. Protozoa
13.3.3.1. Giardiasis
13.3.3.2. Cryptosporidium parvum
13.4. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027
13.4.1. Adults
13.4.2. Children
13.5. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027
13.5.1. Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Online Pharmacies
13.6. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Traveler’s Diarrhea Treatment Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Pathogen
13.7.3. By Age
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Traveler’s Diarrhea Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Traveler’s Diarrhea Market Value Forecast, by Drug Class , 2017–2027
14.2.1. Oral Rehydration Therapy (ORS)
14.2.2. Antidiarrheal Agents
14.2.3. Antibiotics
14.2.3.1. Azithromycin
14.2.3.2. Ciprofloxacin
14.2.3.3. Quinolones
14.2.3.4. Rifaximin
14.2.4. Vaccines/prophylactics
14.2.5. Others
14.3. Latin America Traveler’s Diarrhea Market Value Forecast, by Pathogen, 2017–2027
14.3.1. Bacteria
14.3.1.1. E. Coli
14.3.1.2. Salmonella Spp
14.3.1.3. Others
14.3.2. Viruses
14.3.3. Protozoa
14.3.3.1. Giardiasis
14.3.3.2. Cryptosporidium parvum
14.4. Latin America Traveler’s Diarrhea Market Value Forecast, by Age, 2017–2027
14.4.1. Adults
14.4.2. Children
14.5. Latin America Traveler’s Diarrhea Market Value Forecast, by Distribution Channel, 2017–2027
14.5.1. Retail Pharmacies
14.5.2. Hospital Pharmacies
14.5.3. Online Pharmacies
14.6. Latin America Traveler’s Diarrhea Market Value Forecast, by Country/Sub-region, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Traveler’s Diarrhea Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Pathogen
14.7.3. By Age
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Traveler’s Diarrhea Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2027
15.2.1. Oral Rehydration Therapy (ORS)
15.2.2. Antidiarrheal Agents
15.2.3. Antibiotics
15.2.3.1. Azithromycin
15.2.3.2. Ciprofloxacin
15.2.3.3. Quinolones
15.2.3.4. Rifaximin
15.2.4. Vaccines/prophylactics
15.2.5. Others
15.3. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2027
15.3.1. Bacteria
15.3.1.1. E. Coli
15.3.1.2. Salmonella Spp
15.3.1.3. Others
15.3.2. Viruses
15.3.3. Protozoa
15.3.3.1. Giardiasis
15.3.3.2. Cryptosporidium parvum
15.4. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2027
15.4.1. Adults
15.4.2. Children
15.5. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2027
15.5.1. Retail Pharmacies
15.5.2. Hospital Pharmacies
15.5.3. Online Pharmacies
15.6. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Traveler’s Diarrhea Treatment Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Pathogen
15.7.3. By Age
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis/Ranking By Company (2018)
16.3. Company Profiles
16.3.1. Johnson & Johnson (Johnson & Johnson Consumer Inc.)
16.3.1.1. Company Overview
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Bausch Health Companies Inc. (Salix Pharmaceuticals)
16.3.2.1. Company Overview
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. COSMO PHARMACEUTICALS
16.3.3.1. Company Overview
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Immuron
16.3.4.1. Company Overview
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Valneva SE
16.3.5.1. Company Overview
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Sun Pharmaceutical Industries Ltd.
16.3.6.1. Company Overview
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Norgine
16.3.7.1. Company Overview
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Perrigo Company plc
16.3.8.1. Company Overview
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Bayer AG
16.3.9.1. Company Overview
16.3.9.2. Company Financials
16.3.9.3. SWOT Analysis
List of TablesTable 01: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 02: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027
Table 03: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 04: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria, 2017–2027
Table 05: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa, 2017–2027
Table 06: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age, 2017–2027
Table 07: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 08: Global Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 09: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027
Table 11: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 12: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027
Table 13: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027
Table 14: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027
Table 15: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: North America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 17: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 18: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027
Table 19: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 20: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027
Table 21: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027
Table 22: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027
Table 23: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Europe Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 26: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027
Table 27: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 28: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027
Table 29: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027
Table 30: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027
Table 31: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Asia Pacific Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 33: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 34: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027
Table 35: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 36: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027
Table 37: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027
Table 38: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027
Table 39: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 40: Latin America Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 41: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 42: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2027
Table 43: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 44: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Bacteria 2017–2027
Table 45: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Protozoa 2017–2027
Table 46: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Age 2017–2027
Table 47: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 48: Middle East & Africa Traveler's Diarrhea Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027